Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TAGS
- Sponsors Taiho Pharmaceutical
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 31 May 2016 Data will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) 2016, according to a Taiho Pharmaceutical media release.
- 04 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.